Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 31, 2020 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Appoints Chuck Miller as Senior Vice President of Regulatory Affairs

CAMBRIDGE, Mass., Aug. 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
August 11, 2020 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Receives FDA Fast Track Designation for XMT-1536 for the Treatment of Patients with Platinum-resistant Ovarian Cancer

CAMBRIDGE, Mass., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
August 07, 2020 06:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Second Quarter 2020 Financial Results and Provides Business Update

- Presented positive interim expansion cohort data from XMT-1536 Phase 1 study at ASCO demonstrating a 35% objective response rate, including 10% complete response rate and 80% disease control rate...
August 04, 2020 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
July 31, 2020 08:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Host Conference Call Announcing Second Quarter 2020 Financial Results and Business Updates

CAMBRIDGE, Mass., July 31, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
June 22, 2020 09:05 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Presents Preclinical Data from its Innovative Dolasynthen and Immunosynthen ADC Platforms at American Association for Cancer Research 2020 Virtual Annual Meeting

Preclinical data on XMT-1592, a NaPi2b-targeted site-specific and homogeneous Dolasynthen ADC, demonstrate excellent activity, tolerability and pharmacokineticsPreclinical data on multiple...
June 02, 2020 17:24 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

CAMBRIDGE, Mass., June 02, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc., (Nasdaq:MRSN) a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
May 28, 2020 23:24 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
May 28, 2020 17:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics to Present at Jefferies Virtual Global Healthcare Conference

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of...
May 28, 2020 06:00 ET | Source: Mersana Therapeutics, Inc.

Mersana Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass., May 28, 2020 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (Nasdaq:MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody...